Waystar vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Waystar is a healthcare payments and revenue cycle technology platform processing over $5 trillion in claims annually for hospitals, health systems, and physician groups.
About
Waystar is a healthcare technology company formed through the 2019 merger of ZirMed and Navicure that provides cloud-based revenue cycle management technology to healthcare providers. The platform automates the complex workflows involved in healthcare payments including eligibility verification, claims submission, denial management, payment posting, and patient payment collection. Waystar processes over $5 trillion in annual claims for a network of over 1,000 health plan and payer connections, making it one of the largest healthcare clearinghouse and RCM technology providers in the United States. The company serves hospitals, health systems, physician practices, and ancillary care providers of all sizes through a SaaS platform that integrates with major EHR systems. Waystar went public on Nasdaq in 2024 following years of private equity ownership under EQT Partners. The company uses AI to improve claim accuracy before submission, prioritize denial appeals, and automate patient payment workflows. Waystar's scale and network of payer connections make it a critical piece of healthcare financial infrastructure for providers seeking to improve cash flow and reduce administrative costs.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.